Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxis
Neutralizing mAbs can prevent communicable viral diseases. MK-1654 is a respiratory syncytial virus (RSV) F glycoprotein neutralizing monoclonal antibody (mAb) under development to prevent RSV infection in infants. Development and validation of methods to predict efficacious doses of neutralizing an...
Saved in:
| Published in | EBioMedicine Vol. 73; p. 103651 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Netherlands
Elsevier B.V
01.11.2021
Elsevier |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Neutralizing mAbs can prevent communicable viral diseases. MK-1654 is a respiratory syncytial virus (RSV) F glycoprotein neutralizing monoclonal antibody (mAb) under development to prevent RSV infection in infants. Development and validation of methods to predict efficacious doses of neutralizing antibodies across patient populations exposed to a time-varying force of infection (i.e., seasonal variation) are necessary.
Five decades of clinical trial literature were leveraged to build a model-based meta-analysis (MBMA) describing the relationship between RSV serum neutralizing activity (SNA) and clinical endpoints. The MBMA was validated by backward translation to animal challenge experiments and forward translation to predict results of a recent RSV mAb trial. MBMA predictions were evaluated against a human trial of 70 participants who received either placebo or one of four dose-levels of MK-1654 and were challenged with RSV [NCT04086472]. The MBMA was used to perform clinical trial simulations and predict efficacy of MK-1654 in the infant target population.
The MBMA established a quantitative relationship between RSV SNA and clinical endpoints. This relationship was quantitatively consistent with animal model challenge experiments and results of a recently published clinical trial. Additionally, SNA elicited by increasing doses of MK-1654 in humans reduced RSV symptomatic infection rates with a quantitative relationship that approximated the MBMA. The MBMA indicated a high probability that a single dose of ≥ 75 mg of MK-1654 will result in prophylactic efficacy (> 75% for 5 months) in infants.
An MBMA approach can predict efficacy of neutralizing antibodies against RSV and potentially other respiratory pathogens. |
|---|---|
| AbstractList | Background: Neutralizing mAbs can prevent communicable viral diseases. MK-1654 is a respiratory syncytial virus (RSV) F glycoprotein neutralizing monoclonal antibody (mAb) under development to prevent RSV infection in infants. Development and validation of methods to predict efficacious doses of neutralizing antibodies across patient populations exposed to a time-varying force of infection (i.e., seasonal variation) are necessary. Methods: Five decades of clinical trial literature were leveraged to build a model-based meta-analysis (MBMA) describing the relationship between RSV serum neutralizing activity (SNA) and clinical endpoints. The MBMA was validated by backward translation to animal challenge experiments and forward translation to predict results of a recent RSV mAb trial. MBMA predictions were evaluated against a human trial of 70 participants who received either placebo or one of four dose-levels of MK-1654 and were challenged with RSV [NCT04086472]. The MBMA was used to perform clinical trial simulations and predict efficacy of MK-1654 in the infant target population. Findings: The MBMA established a quantitative relationship between RSV SNA and clinical endpoints. This relationship was quantitatively consistent with animal model challenge experiments and results of a recently published clinical trial. Additionally, SNA elicited by increasing doses of MK-1654 in humans reduced RSV symptomatic infection rates with a quantitative relationship that approximated the MBMA. The MBMA indicated a high probability that a single dose of ≥ 75 mg of MK-1654 will result in prophylactic efficacy (> 75% for 5 months) in infants. Interpretation: An MBMA approach can predict efficacy of neutralizing antibodies against RSV and potentially other respiratory pathogens. Neutralizing mAbs can prevent communicable viral diseases. MK-1654 is a respiratory syncytial virus (RSV) F glycoprotein neutralizing monoclonal antibody (mAb) under development to prevent RSV infection in infants. Development and validation of methods to predict efficacious doses of neutralizing antibodies across patient populations exposed to a time-varying force of infection (i.e., seasonal variation) are necessary. Five decades of clinical trial literature were leveraged to build a model-based meta-analysis (MBMA) describing the relationship between RSV serum neutralizing activity (SNA) and clinical endpoints. The MBMA was validated by backward translation to animal challenge experiments and forward translation to predict results of a recent RSV mAb trial. MBMA predictions were evaluated against a human trial of 70 participants who received either placebo or one of four dose-levels of MK-1654 and were challenged with RSV [NCT04086472]. The MBMA was used to perform clinical trial simulations and predict efficacy of MK-1654 in the infant target population. The MBMA established a quantitative relationship between RSV SNA and clinical endpoints. This relationship was quantitatively consistent with animal model challenge experiments and results of a recently published clinical trial. Additionally, SNA elicited by increasing doses of MK-1654 in humans reduced RSV symptomatic infection rates with a quantitative relationship that approximated the MBMA. The MBMA indicated a high probability that a single dose of ≥ 75 mg of MK-1654 will result in prophylactic efficacy (> 75% for 5 months) in infants. An MBMA approach can predict efficacy of neutralizing antibodies against RSV and potentially other respiratory pathogens. Neutralizing mAbs can prevent communicable viral diseases. MK-1654 is a respiratory syncytial virus (RSV) F glycoprotein neutralizing monoclonal antibody (mAb) under development to prevent RSV infection in infants. Development and validation of methods to predict efficacious doses of neutralizing antibodies across patient populations exposed to a time-varying force of infection (i.e., seasonal variation) are necessary.BACKGROUNDNeutralizing mAbs can prevent communicable viral diseases. MK-1654 is a respiratory syncytial virus (RSV) F glycoprotein neutralizing monoclonal antibody (mAb) under development to prevent RSV infection in infants. Development and validation of methods to predict efficacious doses of neutralizing antibodies across patient populations exposed to a time-varying force of infection (i.e., seasonal variation) are necessary.Five decades of clinical trial literature were leveraged to build a model-based meta-analysis (MBMA) describing the relationship between RSV serum neutralizing activity (SNA) and clinical endpoints. The MBMA was validated by backward translation to animal challenge experiments and forward translation to predict results of a recent RSV mAb trial. MBMA predictions were evaluated against a human trial of 70 participants who received either placebo or one of four dose-levels of MK-1654 and were challenged with RSV [NCT04086472]. The MBMA was used to perform clinical trial simulations and predict efficacy of MK-1654 in the infant target population.METHODSFive decades of clinical trial literature were leveraged to build a model-based meta-analysis (MBMA) describing the relationship between RSV serum neutralizing activity (SNA) and clinical endpoints. The MBMA was validated by backward translation to animal challenge experiments and forward translation to predict results of a recent RSV mAb trial. MBMA predictions were evaluated against a human trial of 70 participants who received either placebo or one of four dose-levels of MK-1654 and were challenged with RSV [NCT04086472]. The MBMA was used to perform clinical trial simulations and predict efficacy of MK-1654 in the infant target population.The MBMA established a quantitative relationship between RSV SNA and clinical endpoints. This relationship was quantitatively consistent with animal model challenge experiments and results of a recently published clinical trial. Additionally, SNA elicited by increasing doses of MK-1654 in humans reduced RSV symptomatic infection rates with a quantitative relationship that approximated the MBMA. The MBMA indicated a high probability that a single dose of ≥ 75 mg of MK-1654 will result in prophylactic efficacy (> 75% for 5 months) in infants.FINDINGSThe MBMA established a quantitative relationship between RSV SNA and clinical endpoints. This relationship was quantitatively consistent with animal model challenge experiments and results of a recently published clinical trial. Additionally, SNA elicited by increasing doses of MK-1654 in humans reduced RSV symptomatic infection rates with a quantitative relationship that approximated the MBMA. The MBMA indicated a high probability that a single dose of ≥ 75 mg of MK-1654 will result in prophylactic efficacy (> 75% for 5 months) in infants.An MBMA approach can predict efficacy of neutralizing antibodies against RSV and potentially other respiratory pathogens.INTERPRETATIONAn MBMA approach can predict efficacy of neutralizing antibodies against RSV and potentially other respiratory pathogens. AbstractBackgroundNeutralizing mAbs can prevent communicable viral diseases. MK-1654 is a respiratory syncytial virus (RSV) F glycoprotein neutralizing monoclonal antibody (mAb) under development to prevent RSV infection in infants. Development and validation of methods to predict efficacious doses of neutralizing antibodies across patient populations exposed to a time-varying force of infection (i.e., seasonal variation) are necessary. MethodsFive decades of clinical trial literature were leveraged to build a model-based meta-analysis (MBMA) describing the relationship between RSV serum neutralizing activity (SNA) and clinical endpoints. The MBMA was validated by backward translation to animal challenge experiments and forward translation to predict results of a recent RSV mAb trial. MBMA predictions were evaluated against a human trial of 70 participants who received either placebo or one of four dose-levels of MK-1654 and were challenged with RSV [NCT04086472]. The MBMA was used to perform clinical trial simulations and predict efficacy of MK-1654 in the infant target population. FindingsThe MBMA established a quantitative relationship between RSV SNA and clinical endpoints. This relationship was quantitatively consistent with animal model challenge experiments and results of a recently published clinical trial. Additionally, SNA elicited by increasing doses of MK-1654 in humans reduced RSV symptomatic infection rates with a quantitative relationship that approximated the MBMA. The MBMA indicated a high probability that a single dose of ≥ 75 mg of MK-1654 will result in prophylactic efficacy (> 75% for 5 months) in infants. InterpretationAn MBMA approach can predict efficacy of neutralizing antibodies against RSV and potentially other respiratory pathogens. |
| ArticleNumber | 103651 |
| Author | Spellman, Daniel S. Caro, Luzelena Roadcap, Brad Maas, Brian M. Bellanti, Francesco Vora, Kalpit A. Witjes, Han Cheung, S.Y. Amy Fok-Seang, Juin Plock, Nele Espeseth, Amy S. Railkar, Radha A. Aliprantis, Antonios O. Lommerse, Jos Huang, Qinlei Guiastrennec, Benjamin Sachs, Jeffrey R. Gao, Wei Kalinova, Mariya Schindler, Emilie Lai, Eseng Qin, Li Catchpole, Andrew P. Chen, Jingxian Zhang, Ying Meng, Jie Stoch, S. Aubrey Liu, Wen |
| Author_xml | – sequence: 1 givenname: Brian M. surname: Maas fullname: Maas, Brian M. organization: Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ 07033, USA – sequence: 2 givenname: Jos surname: Lommerse fullname: Lommerse, Jos organization: Certara, 100 Overlook Center STE 101, Princeton, NJ 08540, USA – sequence: 3 givenname: Nele surname: Plock fullname: Plock, Nele organization: Certara, 100 Overlook Center STE 101, Princeton, NJ 08540, USA – sequence: 4 givenname: Radha A. surname: Railkar fullname: Railkar, Radha A. organization: Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ 07033, USA – sequence: 5 givenname: S.Y. Amy surname: Cheung fullname: Cheung, S.Y. Amy organization: Certara, 100 Overlook Center STE 101, Princeton, NJ 08540, USA – sequence: 6 givenname: Luzelena surname: Caro fullname: Caro, Luzelena organization: Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ 07033, USA – sequence: 7 givenname: Jingxian surname: Chen fullname: Chen, Jingxian organization: Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ 07033, USA – sequence: 8 givenname: Wen surname: Liu fullname: Liu, Wen organization: Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ 07033, USA – sequence: 9 givenname: Ying surname: Zhang fullname: Zhang, Ying organization: Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ 07033, USA – sequence: 10 givenname: Qinlei surname: Huang fullname: Huang, Qinlei organization: Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ 07033, USA – sequence: 11 givenname: Wei surname: Gao fullname: Gao, Wei organization: Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ 07033, USA – sequence: 12 givenname: Li surname: Qin fullname: Qin, Li organization: Certara, 100 Overlook Center STE 101, Princeton, NJ 08540, USA – sequence: 13 givenname: Jie surname: Meng fullname: Meng, Jie organization: Certara, 100 Overlook Center STE 101, Princeton, NJ 08540, USA – sequence: 14 givenname: Han surname: Witjes fullname: Witjes, Han organization: Certara, 100 Overlook Center STE 101, Princeton, NJ 08540, USA – sequence: 15 givenname: Emilie surname: Schindler fullname: Schindler, Emilie organization: Certara, 100 Overlook Center STE 101, Princeton, NJ 08540, USA – sequence: 16 givenname: Benjamin surname: Guiastrennec fullname: Guiastrennec, Benjamin organization: Certara, 100 Overlook Center STE 101, Princeton, NJ 08540, USA – sequence: 17 givenname: Francesco surname: Bellanti fullname: Bellanti, Francesco organization: Certara, 100 Overlook Center STE 101, Princeton, NJ 08540, USA – sequence: 18 givenname: Daniel S. surname: Spellman fullname: Spellman, Daniel S. organization: Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ 07033, USA – sequence: 19 givenname: Brad surname: Roadcap fullname: Roadcap, Brad organization: Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ 07033, USA – sequence: 20 givenname: Mariya surname: Kalinova fullname: Kalinova, Mariya organization: hVivo Services Ltd, 42 New Road, London E1 1JT, UK – sequence: 21 givenname: Juin surname: Fok-Seang fullname: Fok-Seang, Juin organization: hVivo Services Ltd, 42 New Road, London E1 1JT, UK – sequence: 22 givenname: Andrew P. surname: Catchpole fullname: Catchpole, Andrew P. organization: hVivo Services Ltd, 42 New Road, London E1 1JT, UK – sequence: 23 givenname: Amy S. surname: Espeseth fullname: Espeseth, Amy S. organization: Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ 07033, USA – sequence: 24 givenname: S. Aubrey surname: Stoch fullname: Stoch, S. Aubrey organization: Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ 07033, USA – sequence: 25 givenname: Eseng surname: Lai fullname: Lai, Eseng organization: Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ 07033, USA – sequence: 26 givenname: Kalpit A. surname: Vora fullname: Vora, Kalpit A. organization: Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ 07033, USA – sequence: 27 givenname: Antonios O. surname: Aliprantis fullname: Aliprantis, Antonios O. organization: Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ 07033, USA – sequence: 28 givenname: Jeffrey R. surname: Sachs fullname: Sachs, Jeffrey R. email: jeff_sachs@merck.com organization: Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ 07033, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34775220$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkl1rFDEUhgep2Fr7CwSZy3qxaz7nA7EgxWqhIFgV70ImObObdTYZk8zq-Af822Z2a2kLslcJZ877nCHneZodWGchy55jNMcIF69Wc2iMW88JIjhVaMHxo-yIUE5mtC7YwZ37YXYSwgohhDlLxepJdkhZWXJC0FH258L5n9LrXFqde9iAD5BHL23oZDTOyi6Xfe-dVEsIeXR570EbFXNoW6OkGnPX5haGFOnMb2MXCRJ642V0fszDaNUYTYJsjB9Cfvrp-uvLNCqaxukxsVy_HDv5y4Rn2eNWdgFObs7j7MvFu8_nH2ZXH99fnr-9mqmCkjjTXDJJaIspUxgzpCnmNZSoIhWvaF02IAtcIY5bjXALSDVMVRyzVlc1o5rR4-xyx9VOrkTvzVr6UThpxLbg_EJIH43qQJAaY9RWJQOtWaFBIgSU4oYRqSpWTayzHasfmjVoBXZ6hXvQ-1-sWYqF24iqQBQRkgCnNwDvfgwQoliboKDrpAU3BEF4XZZ1zTBPrS_uzrod8m-TqYHuGpR3IXhob1swEpMyYiW2yohJGbFTJqXqByll4nbx6YdNtyf7ZpeFtK-NAS-CMmBV8sODiulBzZ782YO86oxNUnXfYYSwcoNP-gWBRSACietJ6MlnghFijH9LgNf_B-wd_xd1ygib |
| CitedBy_id | crossref_primary_10_1016_j_virs_2025_01_003 crossref_primary_10_1038_s41541_023_00734_7 crossref_primary_10_4155_bio_2022_0097 crossref_primary_10_2174_0115733963267129230919091338 crossref_primary_10_1016_j_biopha_2023_115851 crossref_primary_10_1542_peds_2024_067174 crossref_primary_10_1002_jcph_2284 crossref_primary_10_1016_j_jinf_2024_106325 crossref_primary_10_1016_j_vaccine_2023_05_062 crossref_primary_10_1016_j_antiviral_2023_105791 crossref_primary_10_3389_fimmu_2023_1186184 crossref_primary_10_4155_bio_2023_0081 crossref_primary_10_1080_14656566_2023_2197590 crossref_primary_10_1097_QCO_0000000000000846 crossref_primary_10_1016_j_chom_2021_11_006 crossref_primary_10_1111_cts_13290 crossref_primary_10_1038_s41541_024_00937_6 crossref_primary_10_1016_j_chom_2022_12_010 crossref_primary_10_1016_S1473_3099_22_00291_2 crossref_primary_10_2147_IDR_S373584 crossref_primary_10_1080_21645515_2023_2252289 crossref_primary_10_1016_j_apsb_2025_02_015 crossref_primary_10_1016_j_antiviral_2023_105783 crossref_primary_10_1093_infdis_jiad210 crossref_primary_10_1093_infdis_jiae582 crossref_primary_10_1016_j_chom_2021_12_012 crossref_primary_10_1093_infdis_jiae581 crossref_primary_10_1016_j_virs_2024_09_002 crossref_primary_10_1038_s41467_023_40057_8 crossref_primary_10_3390_pediatric16030057 crossref_primary_10_1016_j_coviro_2023_101337 crossref_primary_10_2147_DHPS_S348727 crossref_primary_10_1208_s12248_022_00753_7 crossref_primary_10_1016_j_ebiom_2022_104264 |
| Cites_doi | 10.1155/2014/571609 10.1002/cpdd.883 10.1038/s41591-021-01377-8 10.1186/s13052-015-0203-x 10.1038/s41541-017-0019-3 10.1126/scitranslmed.aaj1928 10.1093/jpids/piz011 10.1089/vim.2017.0147 10.1128/CVI.00131-10 10.1038/s41467-021-26117-x 10.1016/j.jtbi.2019.01.017 10.1128/AAC.01714-16 10.1001/jama.2020.10245 10.1016/S1473-3099(20)30282-6 10.1371/journal.pone.0175792 10.1016/j.vaccine.2018.09.056 10.1093/biomet/26.4.404 10.1542/peds.2014-1665 10.1097/INF.0000000000000257 10.1080/13543784.2020.1735349 10.1038/sj.ejcn.1602667 10.1038/s41467-019-12137-1 10.1111/irv.12727 10.1177/2040206618770518 10.1097/INF.0000000000001916 10.1016/S1473-3099(15)00247-9 10.1111/j.1442-200X.2006.02179.x 10.1056/NEJMoa1913556 10.1074/jbc.M604292200 |
| ContentType | Journal Article |
| Copyright | 2021 Merck Sharp & Dohme Corp., The Author(s) Merck Sharp & Dohme Corp., The Author(s) Copyright © 2021 Merck Sharp & Dohme Corp., The Author(s). Published by Elsevier B.V. All rights reserved. 2021 Merck Sharp & Dohme Corp., The Author(s) 2021 |
| Copyright_xml | – notice: 2021 Merck Sharp & Dohme Corp., The Author(s) – notice: Merck Sharp & Dohme Corp., The Author(s) – notice: Copyright © 2021 Merck Sharp & Dohme Corp., The Author(s). Published by Elsevier B.V. All rights reserved. – notice: 2021 Merck Sharp & Dohme Corp., The Author(s) 2021 |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
| DOI | 10.1016/j.ebiom.2021.103651 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals (DOAJ) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2352-3964 |
| EndPage | 103651 |
| ExternalDocumentID | oai_doaj_org_article_29110f874edd46dea00e331b42ac8484 PMC8603022 34775220 10_1016_j_ebiom_2021_103651 S235239642100445X 1_s2_0_S235239642100445X |
| Genre | Meta-Analysis Journal Article |
| GroupedDBID | .1- .FO 0R~ 4.4 457 53G 5VS AAEDT AAEDW AAIKJ AALRI AAMRU AAXUO AAYWO ABMAC ACGFS ACVFH ADBBV ADCNI ADEZE ADRAZ ADVLN AEUPX AEXQZ AFPUW AFRHN AFTJW AGHFR AIGII AITUG AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ AOIJS APXCP BCNDV EBS EJD FDB GROUPED_DOAJ HYE HZ~ IPNFZ KQ8 M41 M48 O9- OK1 RIG ROL RPM SSZ Z5R 0SF 6I. AACTN AAFTH AFCTW NCXOZ AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c632t-d5a4a23f134c1140d3159e7082858397bea618051fd01fe0cb4c8514fd8943d43 |
| IEDL.DBID | M48 |
| ISSN | 2352-3964 |
| IngestDate | Wed Aug 27 01:29:59 EDT 2025 Thu Aug 21 18:28:19 EDT 2025 Sun Aug 24 03:28:15 EDT 2025 Thu Apr 24 04:15:02 EDT 2025 Tue Jul 01 00:39:00 EDT 2025 Thu Apr 24 23:04:09 EDT 2025 Tue Jul 25 20:58:57 EDT 2023 Sun Feb 23 10:19:26 EST 2025 Tue Aug 26 16:33:52 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | RSV, Meta-analysis Modelling and Simulation Human Challenge Study Respiratory Syncytial Virus Monoclonal Antibody |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. Copyright © 2021 Merck Sharp & Dohme Corp., The Author(s). Published by Elsevier B.V. All rights reserved. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c632t-d5a4a23f134c1140d3159e7082858397bea618051fd01fe0cb4c8514fd8943d43 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors contributed equally to this work. Present Address: EMD Serono (Business of Merck KGaA, Darmstadt, Germany), Billerica, MA, 01821 USA Present Address: Roche Pharma Research and Early Development, Roche Innovation Center Basel, 4070, Basel, Switzerland Present Address: IntiQuan GmbH, Basel 4051, Switzerland Present Address: Daiichi Sankyo Europe GmbH; 81379 Munich, Germany Present Address: Flagship Pioneering, Inc. Cambridge, MA 02142 USA |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1016/j.ebiom.2021.103651 |
| PMID | 34775220 |
| PQID | 2597799415 |
| PQPubID | 23479 |
| PageCount | 1 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_29110f874edd46dea00e331b42ac8484 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8603022 proquest_miscellaneous_2597799415 pubmed_primary_34775220 crossref_primary_10_1016_j_ebiom_2021_103651 crossref_citationtrail_10_1016_j_ebiom_2021_103651 elsevier_sciencedirect_doi_10_1016_j_ebiom_2021_103651 elsevier_clinicalkeyesjournals_1_s2_0_S235239642100445X elsevier_clinicalkey_doi_10_1016_j_ebiom_2021_103651 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-11-01 |
| PublicationDateYYYYMMDD | 2021-11-01 |
| PublicationDate_xml | – month: 11 year: 2021 text: 2021-11-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | EBioMedicine |
| PublicationTitleAlternate | EBioMedicine |
| PublicationYear | 2021 |
| Publisher | Elsevier B.V Elsevier |
| Publisher_xml | – name: Elsevier B.V – name: Elsevier |
| References | Marshall, Burghaus, Cosson, Cheung, Chenel, DellaPasqua (bib0005) 2016; 5 Griffin, Khan, Esser, Jensen, Takas, Kankam (bib0022) 2017; 61 Lommerse, Plock, Cheung, Sachs (bib0023) 2021; 10 Aliprantis, Wolford, Caro, Maas, Ma, Montgomery (bib0013) 2021; 10 McGuiness, Boron, Saunders, Edelman, Kumar, Rabon-Stith (bib0017) 2014; 33 Lommerse J., Green M., Espeseth A., Vora K.A., Aliprantis A., Finelli L., (Found in) Translation–Cotton rat modelling and validation with model based meta-analysis (MBMA) for RSV. ACoP11, 2020. Mas, Nair, Campbell, Melero, Williams (bib0031) 2018; 36 (bib0009) 2014; 134 Hause, Henke, Avadhanula, Shaw, Tapia, Piedra (bib0030) 2017; 12 Tang, Chen, Cox, Su, Callahan, Fridman (bib0012) 2019; 10 Zhu, McLellan, Kallewaard, Ulbrandt, Palaszynski, Zhang (bib0018) 2017; 9 Plotkin (bib0001) 2010; 17 O'Brien, Chandran, Weatherholtz, Jafri, Griffin, Bellamy (bib0007) 2015; 15 Iversen, Kane, Zeng, Panchal, Warren, Radoshitzky (bib0002) 2020; 20 Roozendaal, Solforosi, Stieh, Serroyen, Straetemans, Wegmann (bib0033) 2021; 12 Lively, Curns, Weinberg, Edwards, Staat, Prill (bib0011) 2019; 8 Boukhvalova, Yim, Blanco (bib0027) 2018; 26 Simões, Forleo-Neto, Geba, Kamal, Yang, Cicirello (bib0015) 2020 Bergeron, Tripp (bib0029) 2020; 29 Marovich, Mascola, Cohen (bib0026) 2020; 324 Dall'Acqua, Kiener, Wu (bib0014) 2006; 281 Khoury, Cromer, Reynaldi, Schlub, Wheatley, Juno (bib0034) 2021 Rhodes, Knight, Kirschner, White, Evans (bib0004) 2019; 465 Fenton, Sauve (bib0020) 2007; 61 Domachowske, Khan, Esser, Jensen, Takas, Villafana (bib0021) 2018; 37 Nakazawa, Saji, Ichida, Oyama, Harada, Kusuda (bib0010) 2006; 48 Liu, Lu, Tabor, Tovchigrechko, Wilkins, Jin (bib0032) 2020; 14 Homaira, Rawlinson, Snelling, Jaffe (bib0003) 2014; 2014 Clopper, Pearson (bib0019) 1934; 26 Page, McKenzie, Bossuyt, Boutron, Hoffmann, Mulrow (bib0016) 2021; 372 Kulkarni, Hurwitz, Simões, Piedra (bib0028) 2018; 31 Bollani, Baraldi, Chirico, Dotta, Lanari, Del Vecchio (bib0008) 2015; 41 Griffin, Yuan, Takas, Domachowske, Madhi, Manzoni (bib0006) 2020; 383 Salazar, Zhang, Fu (bib0025) 2017; 2 Page (10.1016/j.ebiom.2021.103651_bib0016) 2021; 372 Boukhvalova (10.1016/j.ebiom.2021.103651_bib0027) 2018; 26 Tang (10.1016/j.ebiom.2021.103651_bib0012) 2019; 10 Griffin (10.1016/j.ebiom.2021.103651_bib0006) 2020; 383 10.1016/j.ebiom.2021.103651_bib0024 Liu (10.1016/j.ebiom.2021.103651_bib0032) 2020; 14 Lommerse (10.1016/j.ebiom.2021.103651_bib0023) 2021; 10 Griffin (10.1016/j.ebiom.2021.103651_bib0022) 2017; 61 Rhodes (10.1016/j.ebiom.2021.103651_bib0004) 2019; 465 Simões (10.1016/j.ebiom.2021.103651_bib0015) 2020 Marshall (10.1016/j.ebiom.2021.103651_bib0005) 2016; 5 Bergeron (10.1016/j.ebiom.2021.103651_bib0029) 2020; 29 Plotkin (10.1016/j.ebiom.2021.103651_bib0001) 2010; 17 O'Brien (10.1016/j.ebiom.2021.103651_bib0007) 2015; 15 McGuiness (10.1016/j.ebiom.2021.103651_bib0017) 2014; 33 Domachowske (10.1016/j.ebiom.2021.103651_bib0021) 2018; 37 Marovich (10.1016/j.ebiom.2021.103651_bib0026) 2020; 324 Nakazawa (10.1016/j.ebiom.2021.103651_bib0010) 2006; 48 (10.1016/j.ebiom.2021.103651_bib0009) 2014; 134 Homaira (10.1016/j.ebiom.2021.103651_bib0003) 2014; 2014 Aliprantis (10.1016/j.ebiom.2021.103651_bib0013) 2021; 10 Zhu (10.1016/j.ebiom.2021.103651_bib0018) 2017; 9 Mas (10.1016/j.ebiom.2021.103651_bib0031) 2018; 36 Khoury (10.1016/j.ebiom.2021.103651_bib0034) 2021 Bollani (10.1016/j.ebiom.2021.103651_bib0008) 2015; 41 Fenton (10.1016/j.ebiom.2021.103651_bib0020) 2007; 61 Lively (10.1016/j.ebiom.2021.103651_bib0011) 2019; 8 Salazar (10.1016/j.ebiom.2021.103651_bib0025) 2017; 2 Roozendaal (10.1016/j.ebiom.2021.103651_bib0033) 2021; 12 Kulkarni (10.1016/j.ebiom.2021.103651_bib0028) 2018; 31 Iversen (10.1016/j.ebiom.2021.103651_bib0002) 2020; 20 Hause (10.1016/j.ebiom.2021.103651_bib0030) 2017; 12 Dall'Acqua (10.1016/j.ebiom.2021.103651_bib0014) 2006; 281 Clopper (10.1016/j.ebiom.2021.103651_bib0019) 1934; 26 |
| References_xml | – volume: 10 start-page: 1092 year: 2021 end-page: 1106 ident: bib0023 article-title: V2ACHER: Visualization of complex trial data in pharmacometric analysis with covariates publication-title: CPT: Pharmacomet Syst Pharmacol – volume: 9 year: 2017 ident: bib0018 article-title: A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants publication-title: Sci Transl Med – volume: 26 year: 2018 ident: bib0027 article-title: Cotton rat model for testing vaccines and antivirals against respiratory syncytial virus publication-title: Antivir Chem Chemother – volume: 2014 year: 2014 ident: bib0003 article-title: Effectiveness of palivizumab in preventing RSV hospitalization in high risk children: A real-world perspective publication-title: Int J Pediatr – volume: 383 start-page: 415 year: 2020 end-page: 425 ident: bib0006 article-title: Single-dose Nirsevimab for prevention of RSV in preterm infants publication-title: N Engl J Med – volume: 12 start-page: 5877 year: 2021 ident: bib0033 article-title: SARS-CoV-2 binding and neutralizing antibody levels after vaccination with Ad26.COV2.S predict durable protection in rhesus macaques publication-title: Nat Commun – volume: 134 start-page: 415 year: 2014 end-page: 420 ident: bib0009 article-title: Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection publication-title: Pediatrics – volume: 465 start-page: 51 year: 2019 end-page: 55 ident: bib0004 article-title: Dose finding for new vaccines: The role for immunostimulation/immunodynamic modelling publication-title: J Theor Biol – volume: 14 start-page: 403 year: 2020 end-page: 411 ident: bib0032 article-title: Characterization of human respiratory syncytial virus (RSV) isolated from HIV-exposed-uninfected and HIV-unexposed infants in South Africa during 2015-2017 publication-title: Influenza Other Respir Viruses – volume: 10 start-page: 556 year: 2021 end-page: 566 ident: bib0013 article-title: A phase 1 randomized, double-blind, placebo-controlled trial to assess the safety, tolerability, and pharmacokinetics of a respiratory syncytial virus neutralizing monoclonal antibody MK-1654 in healthy adults publication-title: Clin Pharmacol Drug Dev – reference: Lommerse J., Green M., Espeseth A., Vora K.A., Aliprantis A., Finelli L., (Found in) Translation–Cotton rat modelling and validation with model based meta-analysis (MBMA) for RSV. ACoP11, 2020. – volume: 20 year: 2020 ident: bib0002 article-title: Recent successes in therapeutics for Ebola virus disease: no time for complacency publication-title: Lancet Infect Dis – volume: 8 start-page: 284 year: 2019 end-page: 286 ident: bib0011 article-title: Respiratory Syncytial Virus–Associated Outpatient Visits Among Children Younger Than 24 Months publication-title: J Pediat Infect Dis Soc – volume: 26 start-page: 404 year: 1934 end-page: 413 ident: bib0019 article-title: The use of confidence of fiducial limits illustrated in the case of the binomial publication-title: Biometrika – volume: 15 start-page: 1398 year: 2015 end-page: 1408 ident: bib0007 article-title: Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial publication-title: Lancet Infect Dis – volume: 37 start-page: 886 year: 2018 end-page: 892 ident: bib0021 article-title: Safety, tolerability and pharmacokinetics of MEDI8897, an extended half-life single-dose Respiratory Syncytial Virus prefusion F-targeting monoclonal antibody administered as a single Dose to healthy preterm infants publication-title: Pediatr Infect Dis J – volume: 10 start-page: 4153 year: 2019 ident: bib0012 article-title: A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein publication-title: Nat Commun – volume: 2 start-page: 19 year: 2017 ident: bib0025 article-title: An Z. Antibody therapies for the prevention and treatment of viral infections publication-title: NPJ Vaccines – year: 2021 ident: bib0034 article-title: Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection publication-title: Nat Med – volume: 36 start-page: 6660 year: 2018 end-page: 6673 ident: bib0031 article-title: Antigenic and sequence variability of the human respiratory syncytial virus F glycoprotein compared to related viruses in a comprehensive dataset publication-title: Vaccine – volume: 41 start-page: 97 year: 2015 ident: bib0008 article-title: Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV) publication-title: Ital J Pediatr – volume: 48 start-page: 190 year: 2006 end-page: 193 ident: bib0010 article-title: Guidelines for the use of palivizumab in infants and young children with congenital heart disease publication-title: Pediatr Int: Off J Jpn Pediatr Soc – volume: 281 start-page: 23514 year: 2006 end-page: 23524 ident: bib0014 article-title: Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn) publication-title: J Biol Chem – volume: 31 start-page: 195 year: 2018 end-page: 203 ident: bib0028 article-title: Establishing correlates of protection for vaccine development: Considerations for the respiratory syncytial virus vaccine field publication-title: Viral Immunol – volume: 61 start-page: 1380 year: 2007 end-page: 1385 ident: bib0020 article-title: Using the LMS method to calculate z-scores for the Fenton preterm infant growth chart publication-title: Eur J Clin Nutr – volume: 324 start-page: 131 year: 2020 end-page: 132 ident: bib0026 article-title: Monoclonal antibodies for prevention and treatment of COVID-19 publication-title: Jama – volume: 372 start-page: n71 year: 2021 ident: bib0016 article-title: The PRISMA 2020 statement: an updated guideline for reporting systematic reviews publication-title: BMJ (Clin Res Ed) – volume: 5 start-page: 93 year: 2016 end-page: 122 ident: bib0005 article-title: Good practices in model-informed drug discovery and development: practice, application, and documentation publication-title: CPT: Pharmacomet Syst Pharmacol – volume: 29 start-page: 285 year: 2020 end-page: 294 ident: bib0029 article-title: Emerging small and large molecule therapeutics for respiratory syncytial virus publication-title: Expert Opin Investig Drugs – volume: 33 start-page: 589 year: 2014 end-page: 594 ident: bib0017 article-title: Respiratory syncytial virus surveillance in the United States, 2007–2012: results from a national surveillance system publication-title: Pediatr Infect Dis J – year: 2020 ident: bib0015 article-title: Suptavumab for the prevention of medically attended respiratory syncytial virus infection in preterm infants publication-title: Clin Infect Dis An Off Publ Infect Dis Soc Am – volume: 17 start-page: 1055 year: 2010 end-page: 1065 ident: bib0001 article-title: Correlates of protection induced by vaccination publication-title: Clin Vaccine Immunol: CVI – volume: 61 year: 2017 ident: bib0022 article-title: Safety, tolerability, and pharmacokinetics of MEDI8897, the Respiratory syncytial virus prefusion F-targeting monoclonal antibody with an extended half-life, in healthy adults publication-title: Antimicrobial Agents Chemother – volume: 12 year: 2017 ident: bib0030 article-title: Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B publication-title: PloS One – volume: 2014 year: 2014 ident: 10.1016/j.ebiom.2021.103651_bib0003 article-title: Effectiveness of palivizumab in preventing RSV hospitalization in high risk children: A real-world perspective publication-title: Int J Pediatr doi: 10.1155/2014/571609 – volume: 10 start-page: 556 issue: 5 year: 2021 ident: 10.1016/j.ebiom.2021.103651_bib0013 article-title: A phase 1 randomized, double-blind, placebo-controlled trial to assess the safety, tolerability, and pharmacokinetics of a respiratory syncytial virus neutralizing monoclonal antibody MK-1654 in healthy adults publication-title: Clin Pharmacol Drug Dev doi: 10.1002/cpdd.883 – year: 2021 ident: 10.1016/j.ebiom.2021.103651_bib0034 article-title: Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection publication-title: Nat Med doi: 10.1038/s41591-021-01377-8 – volume: 41 start-page: 97 year: 2015 ident: 10.1016/j.ebiom.2021.103651_bib0008 article-title: Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV) publication-title: Ital J Pediatr doi: 10.1186/s13052-015-0203-x – volume: 2 start-page: 19 year: 2017 ident: 10.1016/j.ebiom.2021.103651_bib0025 article-title: An Z. Antibody therapies for the prevention and treatment of viral infections publication-title: NPJ Vaccines doi: 10.1038/s41541-017-0019-3 – volume: 5 start-page: 93 issue: 3 year: 2016 ident: 10.1016/j.ebiom.2021.103651_bib0005 article-title: Good practices in model-informed drug discovery and development: practice, application, and documentation publication-title: CPT: Pharmacomet Syst Pharmacol – volume: 9 issue: 388 year: 2017 ident: 10.1016/j.ebiom.2021.103651_bib0018 article-title: A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants publication-title: Sci Transl Med doi: 10.1126/scitranslmed.aaj1928 – volume: 8 start-page: 284 issue: 3 year: 2019 ident: 10.1016/j.ebiom.2021.103651_bib0011 article-title: Respiratory Syncytial Virus–Associated Outpatient Visits Among Children Younger Than 24 Months publication-title: J Pediat Infect Dis Soc doi: 10.1093/jpids/piz011 – volume: 372 start-page: n71 year: 2021 ident: 10.1016/j.ebiom.2021.103651_bib0016 article-title: The PRISMA 2020 statement: an updated guideline for reporting systematic reviews publication-title: BMJ (Clin Res Ed) – volume: 31 start-page: 195 issue: 2 year: 2018 ident: 10.1016/j.ebiom.2021.103651_bib0028 article-title: Establishing correlates of protection for vaccine development: Considerations for the respiratory syncytial virus vaccine field publication-title: Viral Immunol doi: 10.1089/vim.2017.0147 – volume: 17 start-page: 1055 issue: 7 year: 2010 ident: 10.1016/j.ebiom.2021.103651_bib0001 article-title: Correlates of protection induced by vaccination publication-title: Clin Vaccine Immunol: CVI doi: 10.1128/CVI.00131-10 – volume: 12 start-page: 5877 year: 2021 ident: 10.1016/j.ebiom.2021.103651_bib0033 article-title: SARS-CoV-2 binding and neutralizing antibody levels after vaccination with Ad26.COV2.S predict durable protection in rhesus macaques publication-title: Nat Commun doi: 10.1038/s41467-021-26117-x – volume: 465 start-page: 51 year: 2019 ident: 10.1016/j.ebiom.2021.103651_bib0004 article-title: Dose finding for new vaccines: The role for immunostimulation/immunodynamic modelling publication-title: J Theor Biol doi: 10.1016/j.jtbi.2019.01.017 – volume: 61 issue: 3 year: 2017 ident: 10.1016/j.ebiom.2021.103651_bib0022 article-title: Safety, tolerability, and pharmacokinetics of MEDI8897, the Respiratory syncytial virus prefusion F-targeting monoclonal antibody with an extended half-life, in healthy adults publication-title: Antimicrobial Agents Chemother doi: 10.1128/AAC.01714-16 – volume: 324 start-page: 131 issue: 2 year: 2020 ident: 10.1016/j.ebiom.2021.103651_bib0026 article-title: Monoclonal antibodies for prevention and treatment of COVID-19 publication-title: Jama doi: 10.1001/jama.2020.10245 – volume: 10 start-page: 1092 year: 2021 ident: 10.1016/j.ebiom.2021.103651_bib0023 article-title: V2ACHER: Visualization of complex trial data in pharmacometric analysis with covariates publication-title: CPT: Pharmacomet Syst Pharmacol – volume: 20 issue: 9 year: 2020 ident: 10.1016/j.ebiom.2021.103651_bib0002 article-title: Recent successes in therapeutics for Ebola virus disease: no time for complacency publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(20)30282-6 – volume: 12 issue: 4 year: 2017 ident: 10.1016/j.ebiom.2021.103651_bib0030 article-title: Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B publication-title: PloS One doi: 10.1371/journal.pone.0175792 – volume: 36 start-page: 6660 issue: 45 year: 2018 ident: 10.1016/j.ebiom.2021.103651_bib0031 article-title: Antigenic and sequence variability of the human respiratory syncytial virus F glycoprotein compared to related viruses in a comprehensive dataset publication-title: Vaccine doi: 10.1016/j.vaccine.2018.09.056 – volume: 26 start-page: 404 issue: 4 year: 1934 ident: 10.1016/j.ebiom.2021.103651_bib0019 article-title: The use of confidence of fiducial limits illustrated in the case of the binomial publication-title: Biometrika doi: 10.1093/biomet/26.4.404 – volume: 134 start-page: 415 issue: 2 year: 2014 ident: 10.1016/j.ebiom.2021.103651_bib0009 article-title: Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection publication-title: Pediatrics doi: 10.1542/peds.2014-1665 – volume: 33 start-page: 589 issue: 6 year: 2014 ident: 10.1016/j.ebiom.2021.103651_bib0017 article-title: Respiratory syncytial virus surveillance in the United States, 2007–2012: results from a national surveillance system publication-title: Pediatr Infect Dis J doi: 10.1097/INF.0000000000000257 – volume: 29 start-page: 285 issue: 3 year: 2020 ident: 10.1016/j.ebiom.2021.103651_bib0029 article-title: Emerging small and large molecule therapeutics for respiratory syncytial virus publication-title: Expert Opin Investig Drugs doi: 10.1080/13543784.2020.1735349 – volume: 61 start-page: 1380 issue: 12 year: 2007 ident: 10.1016/j.ebiom.2021.103651_bib0020 article-title: Using the LMS method to calculate z-scores for the Fenton preterm infant growth chart publication-title: Eur J Clin Nutr doi: 10.1038/sj.ejcn.1602667 – year: 2020 ident: 10.1016/j.ebiom.2021.103651_bib0015 article-title: Suptavumab for the prevention of medically attended respiratory syncytial virus infection in preterm infants publication-title: Clin Infect Dis An Off Publ Infect Dis Soc Am – volume: 10 start-page: 4153 issue: 1 year: 2019 ident: 10.1016/j.ebiom.2021.103651_bib0012 article-title: A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein publication-title: Nat Commun doi: 10.1038/s41467-019-12137-1 – volume: 14 start-page: 403 issue: 4 year: 2020 ident: 10.1016/j.ebiom.2021.103651_bib0032 article-title: Characterization of human respiratory syncytial virus (RSV) isolated from HIV-exposed-uninfected and HIV-unexposed infants in South Africa during 2015-2017 publication-title: Influenza Other Respir Viruses doi: 10.1111/irv.12727 – volume: 26 year: 2018 ident: 10.1016/j.ebiom.2021.103651_bib0027 article-title: Cotton rat model for testing vaccines and antivirals against respiratory syncytial virus publication-title: Antivir Chem Chemother doi: 10.1177/2040206618770518 – volume: 37 start-page: 886 issue: 9 year: 2018 ident: 10.1016/j.ebiom.2021.103651_bib0021 article-title: Safety, tolerability and pharmacokinetics of MEDI8897, an extended half-life single-dose Respiratory Syncytial Virus prefusion F-targeting monoclonal antibody administered as a single Dose to healthy preterm infants publication-title: Pediatr Infect Dis J doi: 10.1097/INF.0000000000001916 – volume: 15 start-page: 1398 issue: 12 year: 2015 ident: 10.1016/j.ebiom.2021.103651_bib0007 article-title: Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(15)00247-9 – volume: 48 start-page: 190 issue: 2 year: 2006 ident: 10.1016/j.ebiom.2021.103651_bib0010 article-title: Guidelines for the use of palivizumab in infants and young children with congenital heart disease publication-title: Pediatr Int: Off J Jpn Pediatr Soc doi: 10.1111/j.1442-200X.2006.02179.x – ident: 10.1016/j.ebiom.2021.103651_bib0024 – volume: 383 start-page: 415 issue: 5 year: 2020 ident: 10.1016/j.ebiom.2021.103651_bib0006 article-title: Single-dose Nirsevimab for prevention of RSV in preterm infants publication-title: N Engl J Med doi: 10.1056/NEJMoa1913556 – volume: 281 start-page: 23514 issue: 33 year: 2006 ident: 10.1016/j.ebiom.2021.103651_bib0014 article-title: Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn) publication-title: J Biol Chem doi: 10.1074/jbc.M604292200 |
| SSID | ssj0001542358 |
| Score | 2.403014 |
| SecondaryResourceType | review_article |
| Snippet | Neutralizing mAbs can prevent communicable viral diseases. MK-1654 is a respiratory syncytial virus (RSV) F glycoprotein neutralizing monoclonal antibody (mAb)... AbstractBackgroundNeutralizing mAbs can prevent communicable viral diseases. MK-1654 is a respiratory syncytial virus (RSV) F glycoprotein neutralizing... Background: Neutralizing mAbs can prevent communicable viral diseases. MK-1654 is a respiratory syncytial virus (RSV) F glycoprotein neutralizing monoclonal... |
| SourceID | doaj pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 103651 |
| SubjectTerms | Adolescent Adult Advanced Basic Science Aged Algorithms Antibodies, Monoclonal Antibodies, Neutralizing - administration & dosage Antibodies, Neutralizing - immunology Antibodies, Viral - administration & dosage Antibodies, Viral - immunology Clinical Trials as Topic Female Human Challenge Study Humans Incidence Internal Medicine Male Middle Aged Modelling and Simulation Models, Theoretical Monoclonal Antibody Premedication Research paper Respiratory Syncytial Virus Respiratory Syncytial Virus Infections - epidemiology Respiratory Syncytial Virus Infections - immunology Respiratory Syncytial Virus Infections - prevention & control Respiratory Syncytial Virus, Human - immunology RSV, Meta-analysis Seasons Translational Research, Biomedical - methods Young Adult |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals (DOAJ) dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1bi9UwEA6yIPgi3j3eiOCDgsU2SZP2UcXDIuiD68p5C2mSYuXQLm2P7Nk_4N92Jr1wqrL74mvbJO3MZOZLk_mGkBesVEVeehWlDtYmIsdNQiN5ZLCwRVIkVklMcP70WR6fio-bdHNQ6gvPhA30wIPg3jCYjXGZKeGdE9J5E8ee86QQzNhMZIEJFGLewWJqyA8WmAMaKsulLOK5FBPlUDjc5TG5HVaHLMGsc5kmi7AU2PsX0elv9PnnIcqDqLS-RW6OcJK-HT7jNrnm6zvk-lBgcn-X_Fo3LR6LpaZ2FMma2s7THsPTdvwJSCdScd_RvqFnLW7c9NQjs4Sxe9qUtPa78DvkAqIcdDJvzdNuD54ZPMSW_qzaXUdffjn59gqG6quicXvoqwEdbs151d0jp-sPX98fR2PphchKzvrIpUYYxsuECwsrpthxgD1eBb47gFSq8EYmGUzo0sVJ6WNbCAvYTZQO-dyd4PfJUd3U_iGhSsRl6UD1NpNId5_zwvjcSmezzKTKrgibJK_tyEuO5TG2ejqA9kMHdWlUlx7UtSKv50ZnAy3H5Y-_Q5XOjyKndrgAlqZHS9NXWdqKiMkg9JS2Co4WOqouH1v9q5nvRmfR6UR3TMf6BE0VLZUFFr90syJybjnioQHnXD3k88leNXgL3AIytW92nWZIN5jngNpW5MFgv7NQuFAK0HgML7yw7IXUlnfq6ntgJM8kxArGHv0PMT8mN_BThnzPJ-Sob3f-KQC_vngW5vhvBhVVyQ priority: 102 providerName: Directory of Open Access Journals |
| Title | Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxis |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S235239642100445X https://www.clinicalkey.es/playcontent/1-s2.0-S235239642100445X https://dx.doi.org/10.1016/j.ebiom.2021.103651 https://www.ncbi.nlm.nih.gov/pubmed/34775220 https://www.proquest.com/docview/2597799415 https://pubmed.ncbi.nlm.nih.gov/PMC8603022 https://doaj.org/article/29110f874edd46dea00e331b42ac8484 |
| Volume | 73 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bi9QwFA7LiuCLeHdcXSL4oGClTdKkfRBRcViE9cF1ZN5CmqTryNDuth3Z8Q_4tz2nN60OK_jYaZMM55Lz5XK-Q8gTlqsszb0KYgdrE5HiIaGRPDBY2CLKIqskJjgff5BHC_F-GS_3yFAVtRdgvXNph_WkFtX6xcX59hU4_Mtfd7U85qrDYo9FmEQuMaX6CoQmhSUNjnu836UNC0wNbQvOxSzgqRQDE9HufibRqiX1nwStv0Hpn3crfwtW8xvkeo8y6evOLG6SPV_cIle7upPb2-THvKzwtiw1haPI4VTVnjYYtdb93iAduMZ9TZuSnlV4ntNQj4QTxm5pmdPCb9pdku8Q_KCT8cSe1luYsGHiWNNvq2pT06cfTz4_g6GaVVa6LfRVgmrX5mJV3yGL-btPb4-CviJDYCVnTeBiIwzjecSFhYVU6DigIa9aGjxAWirzRkYJ-Hnuwij3oc2EBUgncoc0707wu2S_KAt_n1Alwjx3YBE2kciCn_LM-NRKZ5PExMrOCBskr21PV45VM9Z6uJf2Vbfq0qgu3alrRp6Pjc46to7LP3-DKh0_Rart9oeyOtW952oG4SDMEyW8c0I6b8LQcx5lghmbiETMiBgMQg_ZrDD_Qkery8dWu5r5enABHema6VCfoKmipbKW3C9ezogcW_YwqYM__x7y8WCvGiYRPBkyhS83tWbIQpimAOZm5F5nv6NQuFAKQHoIf3hi2ROpTd8Uqy8tUXkiIYQw9uD_JHRAruFTl_j5kOw31cY_AgTYZIftzslh69s_AVCcWvw |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Forward+and+reverse+translational+approaches+to+predict+efficacy+of+neutralizing+respiratory+syncytial+virus+%28RSV%29+antibody+prophylaxis&rft.jtitle=EBioMedicine&rft.au=Maas%2C+Brian+M.&rft.au=Lommerse%2C+Jos&rft.au=Plock%2C+Nele&rft.au=Railkar%2C+Radha+A.&rft.date=2021-11-01&rft.pub=Elsevier+B.V&rft.issn=2352-3964&rft.eissn=2352-3964&rft.volume=73&rft_id=info:doi/10.1016%2Fj.ebiom.2021.103651&rft.externalDocID=S235239642100445X |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F23523964%2FS2352396421X00114%2Fcov150h.gif |